Real-World Treatment Choices for AMD

(MedPage Today) -- Poor adherence to anti-VEGF therapy for neovascular age-related macular degeneration (nAMD) remains a major limitation of existing therapies, a review of a large clinical database showed. Almost 40% of patients stopped treatment...